Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at 2022 SAPA Healthcare Investment Forum

2022-06-10
|
Page View:

Banner1.png

We are excited to announce that Medicilon is honored to be the title sponsor at this year’s SAPA Healthcare Investment Forum from June 24-25, 2022. Our CEO Dr. Chun-Lin Chen will be sharing his person experience and strategies on US FDA and China NMPA Dual Filing of IND Submission as well as IPO at the STAR Market.

We welcome you to join us at the forum! Please stop by our booth and chat how our services and capabilities would support your research needs and expedite your drug discovery and development programs.




Investment Forum





Date: June 25, 2022

Location: Hilton East Brunswick, 3 Tower Center Blvd, East Brunswick, NJ


 Poster1.jpg

Agenda1.png

June 25

9:00 - 10:25 a.m.



Agenda2.png

Agenda3.png

Sponsor.png


About SAPA

The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA.  Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with seven chapters and more than 6,000 members. SAPA’s members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production. The organization’s large membership base and superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries. To learn more, please visit their website.

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D services for pharmaceutical enterprises and scientific research institutions around the world.

Based on key links of drug R&D, we focus on the demand for innovation and the development of the global pharmaceutical industry. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.

18+

More Than 18 Years of Experience in New Drug R&D

221 

Projects Successfully Approved with NMPA, FDA, EMA, and TGA

1460+

Active Clients Worldwide

2440+

New Drug Discovery Scientists and Service Personnel

740,000+

Square Feet of Laboratory Floor Space

Share:
Return
Relevant newsRelevant news